<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of clonal <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">blood disorders</z:e> characterized by dyshematopoiesis with a frequent evolution to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Chromosomal deletions rather than translocations are the predominant karyotypic abnormalities in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, suggesting a recessive mechanism in the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, such as inactivation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes </plain></SENT>
<SENT sid="2" pm="."><plain>A group of cyclin-dependent kinase inhibitors, p15 (INK4B), p16 (INK4A), p18 (INK4C) and p19 (INK4D), are candidate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes </plain></SENT>
<SENT sid="3" pm="."><plain>To determine whether genetic alterations of these genes play an important role in the development and/or progression of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, we examined 46 samples from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients by Southern blotting, single-strand-conformation polymorphism (SSCP) using polymerase chain reaction (PCR) and sequencing of DNA </plain></SENT>
<SENT sid="4" pm="."><plain>These samples included 13 <z:hpo ids='HP_0005505'>refractory anemias</z:hpo> (RA), four <z:hpo ids='HP_0004828'>refractory anemias with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), 16 <z:hpo ids='HP_0005505'>refractory anemias</z:hpo> with an excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), eight <z:hpo ids='HP_0005505'>refractory anemias</z:hpo> with an excess of blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) and five <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (CMMoL) samples </plain></SENT>
<SENT sid="5" pm="."><plain>Except for allelic polymorphisms or silent point mutations, no alterations of coding regions of these four CDKI genes were identified </plain></SENT>
<SENT sid="6" pm="."><plain>In summary, genetic abnormalities of the p15, p16, p18 and p19 genes are rare events in the development and/or progression of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>